Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee

European Heart Journal - Cardiovascular Pharmacotherapy · Published 2025-07-18 · DOI 10.1093/ehjcvp/pvaf055

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1093/ehjcvp/pvaf055

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Evaluation and management of heart failure patients with liver disease: European Journal of Heart Failure International Expert Position Paper · European Journal of Heart Failure · 2026 · Cites or is cited by this article
• Treatment Strategies in Incident and Recurrent Hyperkalemia: Insights from the TRACK Study · ADVANCES IN THERAPY · 2026 · Cites or is cited by this article
• Beta-blockers after myocardial infarction: time to change the guidelines · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Why does research integrity affect us all? · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Innovation and constraints in cardiovascular pharmacotherapy · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Why cardio-rheumatology? · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal
• Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Real-world evidence of finerenone in Type 2 diabetes: addressing confounding and follow-up duration · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal